S. Dan Costa

GPER Promoter Methylation Controls GPER Expression in Breast Cancer Patients

Christine Weissenborn, T. Ignatov, A. Zenclussen, 2017, Cancer investigation.

Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study

M. Rezai, M. Beckmann, P. Fasching, 2015, International journal of cancer.

Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.

A. Schneeweiss, C. Denkert, S. Loibl, 2016, The Lancet. Oncology.

Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.

M. Rezai, P. Fasching, T. Kühn, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial

A. Schneeweiss, C. Denkert, S. Loibl, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.

Peter A Fasching, Mahdi Rezai, Keyur Mehta, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Endometrial cancer after ulipristal acetate for uterine fibroma.

T. Ignatov, A. Ignatov, H. Eggemann, 2017, European journal of obstetrics, gynecology, and reproductive biology.